Group 1 - Shanghai's GDP reached 1.27 trillion yuan in Q1, with a year-on-year growth of 5.1% [1] - The information transmission, software, and IT services sector contributed over 60% to the city's GDP growth, with a value added of 172.61 billion yuan, growing 13.0% year-on-year [1] - The financial sector added 218.33 billion yuan, with a year-on-year growth of 9.4%, contributing 4.3 percentage points above the overall GDP growth rate [1] Group 2 - Shanghai's industrial production accelerated, with an industrial value added growth of 3.6% and total industrial output growth of 3.5%, an increase of 2.8 percentage points compared to the previous year [1] - Key industries such as computer, communication, and electronic equipment manufacturing saw a production value increase of 23.3%, while transportation equipment manufacturing grew by 22.6% [1] - The three leading industries—artificial intelligence, biomedicine, and integrated circuits—saw a manufacturing output growth of 7.2%, outpacing the overall industrial output growth by 3.7 percentage points [2] Group 3 - The artificial intelligence manufacturing sector grew by 13.2%, integrated circuits by 8.9%, and biomedicine by 2.8% [2] - New industrial products showed rapid growth, with industrial robot production increasing by 18.6% and semiconductor storage disk production by 18.4% [2] - Investment in emerging sectors like integrated circuits and biomedicine surged, with electronic information product manufacturing investment up by 37.6% and biomedicine investment by 17.6%, driving overall manufacturing investment growth of 23.4% [2]

优势领域增势强劲。 上海市统计局4月23日发布的数据显示，一季度全市实现地区生产总值1.27万亿元，按不变价格计算，同 比增长5.1%。其中，优势领域增势强劲，一季度全市信息传输、软件和信息技术服务业以及金融业增势强 劲，对全市GDP增长的贡献率合计超六成。 据统计，一季度上海市信息传输、软件和信息技术服务业增加值1726.09亿元，同比增长13.0%，高出全市 GDP增速7.9个百分点；金融业增加值2183.29亿元，同比增长9.4%，高出全市GDP增速4.3个百分点。 一季度，上海工业生产增长加快，先导产业持续发力。数据显示，全市工业增加值同比增长3.6%，规模以 上工业总产值同比增长3.5%，增速比上年全年加快2.8个百分点。计算机、通信和其他电子设备制造业产 值同比增长23.3%，铁路、船舶、航空航天和其他运输设备制造业增长22.6%，电气机械和器材制造业增 长9.0%。 人工智能、生物医药、集成电路是上海三大先导产业。据统计，一季度，三大先导产业制造业总产值同比 增长7.2%，增速快于全市规模以上工业总产值3.7个百分点。其中，人工智能制造业产值增长13.2%，集成 电路制造业增长8.9%，生物医药 ...

Core Insights - The company reported a significant revenue growth of 16.80% year-on-year, reaching 784 million yuan in total revenue for 2024, while net profit decreased by 10.59% to 24 million yuan, indicating challenges in cost control and investment returns [1][5]. Group 1: Revenue and Profitability - The company's total revenue for 2024 was 784 million yuan, with a year-on-year growth of 16.80% [1]. - Gross profit reached 257 million yuan, reflecting an 11.74% increase compared to the previous year [1]. - The net profit attributable to shareholders was 24 million yuan, showing a decline of 10.59% year-on-year, while the non-recurring net profit was 107 million yuan, up 23.69% [1][5]. Group 2: Business Segments - The main business includes the research, manufacturing, and sales of precision components such as needle bearings and one-way clutches, with revenue from traditional automotive and motorcycle sectors growing by 17.52% and 18.78%, respectively [4]. - The new energy vehicle (NEV) components business generated revenue of 81.3 million yuan, accounting for 10.37% of total revenue, marking it as a new growth point for the company [4]. Group 3: Cost Control and Investment Management - The decline in net profit is attributed to a loss of 103 million yuan from changes in the fair value of non-current financial assets, highlighting issues in cost control and investment returns [5][6]. - The company experienced significant volatility in investment returns, with non-recurring losses amounting to 83.07 million yuan, primarily due to a loss of 99.06 million yuan from non-current financial assets [6]. Group 4: Strategic Initiatives - The establishment of the Southern Changsheng NEV components division indicates the company's proactive approach to expanding its market share in the NEV sector [4]. - The company's diversification into integrated circuits and industrial robotics is beginning to show results, although these segments currently represent a small portion of total business [6].

21世纪经济报道记者王峰 北京报道 4月23日，最高人民检察院举行"以高质效知识产权检察履职 服务高 水平科技创新"新闻发布会，发布《知识产权检察工作白皮书（2024）》（下称"白皮书"），通报检察 机关加强知识产权司法保护工作整体情况。 值得注意的是，近日，最高检经研究并报中央机构编制委员会办公室批复同意，在最高检经济犯罪检察 厅加挂"知识产权检察厅"牌子。4月23日的新闻发布会是最高检知识产权检察厅第一次向社会公众亮 相。最高检知识产权检察厅正式挂牌成立，标志着我国知识产权司法保护进一步迈入专业化、综合化的 发展阶段。 2024年，全国检察机关共受理审查逮捕侵犯知识产权犯罪13486人，受理审查起诉33805人，同比分别上 升5.9%和10.2%。 最高人民检察院党组成员、副检察长宫鸣在发布会上介绍，检察机关聚焦新一代信息技术、人工智能、 高端装备、生物医药、集成电路等关键核心技术，加强知识产权司法保护，为高质量发展创造安全稳定 环境，服务因地制宜发展新质生产力。 依法加强关键核心技术刑事保护 白皮书介绍，2024年，全国检察机关共受理审查起诉侵犯商业秘密犯罪163件385人，案件数同比上升 12.4%。 ...

Financial Performance - In 2024, the company achieved a total revenue of 546.87 million yuan, representing a year-on-year growth of 14.50% [2] - The net profit for 2024 was 80.27 million yuan, reflecting a decline of 37.68% compared to the previous year [10][19] - The operating cash flow net amount was 46.90 million yuan, which was insufficient to support high R&D investments and business expansion needs [5] R&D and Product Development - The company increased its R&D investment by 33.49% in 2024, focusing on enhancing existing products and developing new technologies [23] - Key technologies developed include addressable test chip design, ultra-high-density arrays, and rapid electrical parameter testing [4] - The company plans to expand its product matrix, including the development of new EDA software and testing equipment [15] Market Position and Strategy - The company aims to become a world-leading supplier of EDA software and wafer-level electrical testing equipment [5] - The domestic integrated circuit industry is expected to benefit from the investment from major funds, providing more business opportunities [4] - The company has a strong focus on market expansion and is actively seeking to establish overseas subsidiaries to enhance its international presence [20] Talent and Workforce - The workforce increased from 500 to 635 employees in 2024, with a significant portion in the technical department [5] - The company emphasizes employee training and development to enhance skills and meet long-term growth needs [5] Customer and Market Dynamics - The company’s customer base includes leading wafer manufacturers and top-tier chip design companies, which are financially robust [6] - The company’s overseas sales accounted for less than 3% of total revenue, indicating limited exposure to international market risks [10][18] - The company is exploring collaborations with universities and research institutions to enhance its market competitiveness [15] Challenges and Future Outlook - The decline in net profit is attributed to increased R&D spending and a slowdown in revenue growth [10][19] - The company is optimistic about future growth, anticipating multiple performance growth points as new products are commercialized [11] - The semiconductor industry is expected to grow rapidly due to advancements in AI and increased demand for automotive electronics [22]

作 者丨王峰 编 辑丨 包芳鸣 图 源丨图虫 本轮本科专业调整力度达到新高度。 日前，教育部公布2 0 2 4年度普通高等学校本科专业备案和审批结果，全国高校共新增 专业点1 8 3 9个，调整学位授予门类或修业年限专业点1 5 7个，停招专业点2 2 2 0个，撤 销专业点1 4 2 8个，专业调整优化力度进一步加大。 《教育强国建设规划纲要（2 0 2 4—2 0 3 5年）》中多处提及学科专业建设，提出"超常布局急需 学科专业，加强基础学科、新兴学科、交叉学科建设，支持濒危学科和冷门学科" "超前布局、 动 态 调 整 学 科 专 业 " " 面 向 数 字 经 济 和 未 来 产 业 发 展 ， 加 强 课 程 体 系 改 革 ， 优 化 学 科 专 业 设 置"等。 2 1世纪经济报道记者梳理发现 ，人工智能专业位居2 0 2 4年度新增专业点数量之首，共新增9 1 所布点高校， 数字经济、智能建造、大数据管理与应用、城乡规划、智能制造工程、机器人 工程、集成电路设计与集成系统等新增专业点数量位居其后，布点高校数量都超过3 0所。 此次还增设2 9种新专业，包括北京航空航天大学等6所高校超常增设的低 ...

本报记者 郝亚娟 张荣旺 上海 北京报道 在"投早投小投硬科技"政策导向下，各地正竞速布局天使投资生态圈。在由上海科创金融研究院和上海 天使会联合主办的"2025天使投资大会"上，上海国投公司党委书记、董事长袁国华指出，未来将与上海 天使会共同打造产业生态的创新之和，畅通资本科技产业人才的桥梁，构建覆盖资金支持、技术孵化、 市场验证、政策借鉴的全链条的早期生态服务体系。 上海经邑产业数智研究院副院长沈佳庆在接受《中国经营报》记者采访时指出，天使投资是科技创新 的"最先一公里"，尤其在"硬科技"领域（如人工智能、新材料等），直接推动技术突破和产业升级。天 使投资往往超越财务回报，关注项目是否创造社会价值，例如提升人类福祉或解决重大科技难题等。 国资重构早期投资逻辑 天使投资是创业公司的"第一桶金"。在科技创新成为国家战略的背景下，政府基金和私募机构越来越关 注天使投资。 国务院办公厅《关于做好金融"五篇大文章"的指导意见》，提出发挥多层次资本市场支持科技创新关键 枢纽作用，着力投早、投小、投长期、投硬科技。丰富支持国家重大科技任务的金融政策和工具，健全 重大技术攻关风险分散机制。优化科技型中小企业融资环境，发展 ...

公司代码：688130 公司简称：晶华微 第一节 重要提示 1、本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投 资者应当到www.sse.com.cn网站仔细阅读年度报告全文。 2、重大风险提示 公司已在本年度报告中详细描述可能存在的风险，敬请查阅本报告"第三节 管理层讨论与分析 四、风险 因素"相关内容，请投资者予以关注。 3、本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、完整 性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 4、公司全体董事出席董事会会议。 5、天健会计师事务所（特殊普通合伙）为本公司出具了带有强调事项段的无保留意见的审计报告，本 公司董事会、监事会对相关事项已有详细说明，请投资者注意阅读。 天健会计师事务所（特殊普通合伙）对本公司 2024 年度财务报表出具了带有强调事项段的无保留意见 的审计报告，公司董事会、监事会对 2024 年度财务报表非标准审计意见涉及事项进行了专项说明，详 见公司同日在上海证券交易所网站（www.sse.com.cn）披露的专项说明全文。 6、公司上市时未盈利且尚未 ...

Core Viewpoint - Wan Sheng Intelligent is expanding its business scope to include integrated circuit design and manufacturing, reflecting its ambition to grow beyond its current operations in smart metering and IoT sectors [1][2]. Business Expansion - The company announced plans to change its business scope to include "integrated circuit design; manufacturing of integrated circuit chips and products; design and services of integrated circuit chips; and sales of integrated circuit chips and products" [1][2]. - The board and supervisory committee have approved the proposal for changing the business scope and amending the company’s articles of association [2]. Financial Performance - Wan Sheng Intelligent experienced significant revenue fluctuations in recent years. In 2021, the company reported revenue of 546 million yuan, a decrease of 4.34% year-on-year, and a net profit of 65.18 million yuan, down 25.37% [5]. - The company rebounded in 2022 and 2023, with revenues of 844 million yuan and 1.119 billion yuan, representing year-on-year growth of 54.52% and 32.60%, respectively. Net profits for the same years were 135 million yuan and 250 million yuan, with increases of 107.39% and 85.01% [5]. - For 2024, the company anticipates a decline in net profit to between 110 million and 140 million yuan, a decrease of 44.02% to 56.01% year-on-year, influenced by customer order delivery schedules and increased market competition [6]. Research and Development - The company has maintained a high level of investment in research and development, with R&D expenses for 2021, 2022, and 2023 being 47.45 million yuan, 57.55 million yuan, and 58.56 million yuan, reflecting year-on-year growth of 34.15%, 21.29%, and 1.76% respectively [9]. - As of the first three quarters of 2024, R&D expenses reached 54.38 million yuan, a year-on-year increase of 32.25%, with an average R&D expense ratio of approximately 6.8% over the past four years [9]. Order Book and Market Position - As of the end of 2024, Wan Sheng Intelligent has a cumulative order book of 1.09 billion yuan, a 40.48% increase compared to the same period last year [8]. - The company has secured a project worth 223 million yuan from the Southern Power Grid, which is expected to positively impact future operating performance [9].

Group 1: Zhongjuxin - In 2024, Zhongjuxin's revenue will primarily come from the integrated circuit sector, accounting for nearly 74% of total revenue, with a slow recovery in semiconductor market demand [1] - The photovoltaic industry is experiencing negative gross margins, and the company will focus on integrated circuit clients in the future [1] - Electronic specialty gases generated revenue of 247 million yuan with a gross margin of 20.70%, mainly from high-purity chlorine [1] - The second phase of electronic specialty gases products will enhance gross margins, while the electronic wet chemical segment is facing declining margins due to industry competition [1] - The company reported a loss in Q4 due to increased labor costs, R&D investments, and year-end project expenses [1] - Overseas sales revenue is approximately 90 million yuan, with sales to the U.S. accounting for less than 1% of total revenue, indicating limited impact [1] - The company plans to expand market efforts and overseas sales channels in 2025 [1] Group 2: Jiuzhou Pharmaceutical - Jiuzhou Pharmaceutical indicated that the suspension of the PLI plan in India benefits raw material drug manufacturers in other countries, with domestic raw material prices stabilizing [2] - The CDMO business is expected to see a 15% year-on-year increase in new projects and a 20% increase in contract value in 2024, with revenue nearing 3.9 billion yuan and nearly 80% from overseas clients [2] - The company anticipates a recovery of CDMO gross margins to around 40% by 2025 [2] - In Q1, the overall capacity utilization rate was approximately 60%, with capital expenditures planned to be controlled at 500-600 million yuan in 2025 [2] - The company aims to introduce leading talents in the fields of peptides, DC, and small nucleic acids over the next three years [2] - Jiuzhou Pharmaceutical plans to provide services to over 70 clients in 2024, with nearly 30 new clients onboarded, focusing on inhalation formulations and liposome technology platforms [2]